Skip to main content
. 2019 Aug 29;11(9):1268. doi: 10.3390/cancers11091268

Figure 3.

Figure 3

Combined treatment of CL4 and anti-PD-L1 mAb efficiently inhibits tumor cell survival. SK-BR-3 (A), LNCaP (B), and MCF-7 (C) cells were treated for 72 h with CL4 or 10_12 mAb, alone or in combination, at the indicated concentrations. Cell survival is expressed as percent of viable treated cells with respect to untreated cells. CL4Sc was used in parallel as a negative control. Error bars depict means ± SD. p-values for the indicated mAbs relative to untreated cells, and for CL4 relative to CL4Sc, are: *** p ≤ 0.001; ** p < 0.01; * p < 0.05.